Insider Ownership

Name Relationship / Title Current Shares Trading Activity
adelman robert j Director 3,340,139 View
barker jason Officer 10,000 View
baskett forest Beneficial Owner (10% or more) 4,469,274 View
drant ryan d Beneficial Owner (10% or more) 4,469,274 View
druzgala pascal Officer 205,288 View
evnin luke Beneficial Owner (10% or more) 5,364,572 View
goddard paul Officer 125,520 View
growth equity opportunities fund, llc Beneficial Owner (10% or more) 4,469,274 View
kerins patrick j Beneficial Owner (10% or more) 4,469,274 View
kolluri krishna kittu Beneficial Owner (10% or more) 4,469,274 View
linehan charles m Beneficial Owner (10% or more) 4,469,274 View
milner peter g Officer 319,520 View
mpm bioventures iii-qp l.p. Beneficial Owner (10% or more) 5,364,572 View
nomura phase4 ventures ltd Beneficial Owner (10% or more) 2,447,731 View
orbimed advisors llc Beneficial Owner (10% or more) 1,340,139 View
simon nicholas j iii Director 5,368,974 View
trainor iii eugene a Beneficial Owner (10% or more) 4,469,274 View

Stock transaction information provided by EDGAR Online. ARYx Therapeutics makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.

Stock Information
NASDAQ:ARYX
$0.46   - 0.02
Jul 29, 2010
3:33 PM ET
Quotes delayed at least 20 minutes.
Information provided by eSignal.
 ARYx Therapeutics Final
     Prospectus

Corporate Presentation

Learn more about our products, technology, and financial history by viewing our Corporate Presentation.

Learn More